Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $3M | $14M | — | — | — | — |
| Enterprise Value | $4M | $16M | — | — | — | — |
| P/E Ratio → | -0.25 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -2.3% | 1.7% |
| ROA | -610.9% | -610.9% | -79.2% | -12.3% | -2.0% | 1.6% |
| ROIC | — | — | — | -22.0% | -1.5% | — |
| ROCE | — | — | — | -46.0% | -1.9% | -0.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 12.75 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | 0.02 |
| Net Debt / Equity | — | — | — | — | 8.85 | -0.00 |
| Net Debt / EBITDA | — | — | — | — | — | -0.06 |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -46.27 | -46.27 | -19.89 | -6.22 | -12.37 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Quick Ratio | 0.05 | 0.05 | 0.09 | 0.04 | 0.10 | 0.31 |
| Cash Ratio | 0.03 | 0.03 | 0.09 | 0.08 | 1.41 | 0.24 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $24M | $7M | $8M | $34M | $35M |
Imminent liquidity exhaustion
As reported in financial statements, Liminatus Pharma's ROIC of -9.8% in 2023Q4 highlights a fundamental inability to generate returns on invested capital, a trend that appears to have worsened as the company continues to burn through its limited resources without achieving any meaningful clinical or commercial milestones.
The negative return on capital metrics suggest that the company's R&D expenditures are not currently translating into tangible asset growth or value creation. Investors should monitor whether the firm can pivot toward a more efficient capital allocation strategy, as the current trajectory indicates a persistent decay in shareholder value.
Based on the company's reported figures, the current ratio plummeted to a critical 0.05 in 2025Q4, indicating that the firm lacks the necessary liquid assets to cover its immediate short-term obligations and faces a severe risk of insolvency without an urgent and substantial capital infusion.
The collapse in liquidity ratios suggests that the company is operating on a razor-thin margin of safety, leaving it highly susceptible to even minor operational disruptions. This precarious position warrants further investigation into the firm's ability to secure bridge financing or avoid a forced restructuring of its existing debt obligations.
According to recent SEC filings and peer data, Liminatus lags behind clinical-stage competitors like Kymera Therapeutics, which maintain significantly stronger balance sheets, suggesting that the company's structural inability to secure long-term funding is a unique competitive disadvantage that may limit its ability to reach critical clinical inflection points.
While peers in the biotechnology sector often face high volatility, the gap between Liminatus and its better-capitalized counterparts appears structural rather than temporary. This disparity suggests that the company may struggle to attract the institutional support necessary to compete effectively in the high-cost CAR-T development landscape.
As indicated by the historical data, the use of P/E or EV/EBITDA multiples is fundamentally inappropriate for Liminatus, as these metrics obscure the reality of a pre-revenue entity where the primary value driver is clinical data rather than current earnings or operational cash flow generation.
Analysts should instead focus on 'cash runway' and 'burn-to-milestone' metrics to assess the company's viability. Relying on traditional valuation ratios in this context may lead to a dangerous misinterpretation of the firm's financial health, as it ignores the binary nature of its clinical-stage business model.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LIMN stock.
Liminatus Pharma, Inc. Class A Common Stock's current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Based on historical data, Liminatus Pharma, Inc. Class A Common Stock is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.